These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28145664)

  • 1. AAN Updates Guidelines on the Uses of Botulinum Neurotoxin.
    Wilkes J
    Am Fam Physician; 2017 Feb; 95(3):198-199. PubMed ID: 28145664
    [No Abstract]   [Full Text] [Related]  

  • 2. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Simpson DM; Hallett M; Ashman EJ; Comella CL; Green MW; Gronseth GS; Armstrong MJ; Gloss D; Potrebic S; Jankovic J; Karp BP; Naumann M; So YT; Yablon SA
    Neurology; 2016 May; 86(19):1818-26. PubMed ID: 27164716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical guidelines: No more mistaken identities for botulinum neurotoxins.
    Albanese A
    Nat Rev Neurol; 2016 Jul; 12(7):373-4. PubMed ID: 27313106
    [No Abstract]   [Full Text] [Related]  

  • 4. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
    Hubble J; Schwab J; Hubert C; Abbott CC
    Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of botulinum toxin type A in the management of adult-onset focal spasticity: a survey of Australian allied health professionals.
    Williams G; Olver J; de Graaff S; Singer BJ
    Aust Occup Ther J; 2012 Aug; 59(4):257-64. PubMed ID: 22934898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Focal dystonias and their treatment with dysport (botulinum toxin type A)].
    Orlova OR; Timerbaeva SL; Khat'kova SE; Kotliarov VV; Korenko LA; Zalialova ZA; Fal'kovskiĭ IV; Shperling LP; Antipova LN; Antipenko EA; Mingazova LR; Soĭkher MI; Krasavina DA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):81-9. PubMed ID: 22951787
    [No Abstract]   [Full Text] [Related]  

  • 7. Botulinum neurotoxin in muscle overactivity.
    Esquenazi A
    J Head Trauma Rehabil; 2005; 20(6):563-7. PubMed ID: 16304491
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.
    Albrecht P; Jansen A; Lee JI; Moll M; Ringelstein M; Rosenthal D; Bigalke H; Aktas O; Hartung HP; Hefter H
    Neurology; 2019 Jan; 92(1):e48-e54. PubMed ID: 30464031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of botulinum toxins.
    Naumann M; Boo LM; Ackerman AH; Gallagher CJ
    J Neural Transm (Vienna); 2013 Feb; 120(2):275-90. PubMed ID: 23008029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of botulinum neurotoxin for spasticity].
    Mukai Y; Kaji R
    Brain Nerve; 2008 Dec; 60(12):1421-6. PubMed ID: 19110753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm.
    Johnstone SJ; Adler CH
    Headache; 1998 May; 38(5):366-8. PubMed ID: 9630789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Own experience with botulinum treatment of dystonia].
    Domzał T
    Neurol Neurochir Pol; 1995; 29(4):481-8. PubMed ID: 8544926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology and the practice committee of the child neurology society.
    Whelan MA; Delgado MR
    Neurology; 2010 Aug; 75(7):669. PubMed ID: 20713958
    [No Abstract]   [Full Text] [Related]  

  • 16. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum neurotoxin treatment for spasticity: the role of electromyography guidance.
    Vilholm OJ; Nielsen JB
    J Rehabil Med; 2014 Jul; 46(7):715-6. PubMed ID: 24687222
    [No Abstract]   [Full Text] [Related]  

  • 19. Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy.
    Walter U; Mühlenhoff C; Benecke R; Dressler D; Mix E; Alt J; Wittstock M; Dudesek A; Storch A; Kamm C
    Neurology; 2020 May; 94(20):e2109-e2120. PubMed ID: 32332130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new botulinum toxin potentially bioequivalent to onabotulinumtoxinA: are there any differences at all?
    Yang GH; Jung HH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):165-70. PubMed ID: 23301820
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.